DAX25.262 +0,5%Est505.997 +1,6%MSCI World4.343 -0,1%Top 10 Crypto12,02 -1,3%Nas23.671 +0,8%Bitcoin78.874 +0,9%Euro1,1667 +0,3%Öl63,54 +0,8%Gold4.576 +1,5%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Novo Nordisk A3EU6F Rheinmetall 703000 Deutsche Telekom 555750 Allianz 840400 Amazon 906866 Infineon 623100 Bayer BAY001 BASF BASF11 Volkswagen (VW) vz. 766403 DroneShield A2DMAA Lufthansa 823212 Siemens Energy ENER6Y SAP 716460 Siemens 723610
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Börsen gehen stärker ins Wochenende -- DAX schließt nach Rekord höher -- Tilray übertrifft Erwartungen -- TUI, Alphabet, BMW, BioNTech, Rheinmetall, DroneShield, Rio Tinto, Merck & Co. im Fokus
Top News
Ausblick: JPMorgan Chase legt die Bilanz zum abgelaufenen Quartal vor Ausblick: JPMorgan Chase legt die Bilanz zum abgelaufenen Quartal vor
Ausblick: Delta Air Lines stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor Ausblick: Delta Air Lines stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
10 DAX-Trends für 2026: Diese Börsentrends erwarten Aktienmarktanalysten für 2026. Starten Sie gut informiert ins neue Börsenjahr. Jetzt lesen!

Alkermes Aktie

Kaufen
Verkaufen
25,20 EUR -0,20 EUR -0,79 %
STU
29,65 USD +0,05 USD +0,17 %
BTT
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.4,20 Mrd. EUR

KGV13,26Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1JKVH

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINIE00B56GVS15

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolALKS

Alkermes Aktien News

DatumMeistgelesen
PR NewswireAlkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
PR NewswireAlkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
PR NewswireAlkermes to Participate in Two Upcoming Investor Conferences
PR NewswireAlkermes to Participate in Two Upcoming Investor Conferences
PR NewswireAlkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
PR NewswireAlkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
PR NewswireAlkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
PR NewswireAlkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
PR NewswireAlkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
PR NewswireAlkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
PR NewswireAlkermes plc Reports First Quarter 2024 Financial Results
PR NewswireAlkermes plc Reports First Quarter 2024 Financial Results
PR NewswireAlkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
PR NewswireAlkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
PR NewswireAlkermes to Report First Quarter Financial Results on May 1, 2024
PR NewswireAlkermes to Report First Quarter Financial Results on May 1, 2024
PR NewswireAlkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
PR NewswireAlkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
PR NewswireAlkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
PR NewswireAlkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
PR NewswireAlkermes Announces Appointment of Nancy S. Lurker to Board of Directors
PR NewswireAlkermes Announces Appointment of Nancy S. Lurker to Board of Directors
PR NewswireAlkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
PR NewswireAlkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
PR NewswireAlkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024
PR NewswireAlkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024
PR NewswireAlkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PR NewswireAlkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PR NewswireAlkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)
PR NewswireAlkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)
PR NewswireAlkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk
PR NewswireAlkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk
PR NewswireUber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
PR NewswireAlkermes to Participate in Two Upcoming Investor Conferences
PR NewswireAlkermes to Participate in Two Upcoming Investor Conferences
PR NewswireAlkermes Completes Separation of Oncology Business
PR NewswireAlkermes Completes Separation of Oncology Business
PR NewswireAlkermes to Participate in the Jefferies London Healthcare Conference
PR NewswireAlkermes to Participate in the Jefferies London Healthcare Conference
PR NewswireAlkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement

Alkermes News

Alkermes News: auf dieser Seite finden Sie alle Alkermes News und Nachrichten zur Alkermes Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Alkermes News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Alkermes News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.